New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
ZEISS and Alpenglow Biosciences join forces to transform clinical pathology with cutting-edge light sheet microscopy and AI-driven analysis, enhancing patient care through precise treatment recommendations.
Share
By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets).
"Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice."
'We are excited to collaborate with Alpenglow and leverage their deep expertise in AI and software development," said Dr. Michael Albiez, Head of ZEISS Research Microscopy Solutions. "This partnership combines Alpenglow's rapidly growing reputation with pharmaceutical companies and clinicians with the leadership of ZEISS in light-sheet microscopy, enabling the creation of powerful, fully integrated workflows for 3D pathology, from sample to analytics.'
Dr. Albiez further emphasized, 'At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments."
The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making.
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
ZEISS Research Microscopy Solutions
ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.
Further information at www.zeiss.com/microscopy
About Alpenglow Biosciences
Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at alpenglowbiosciences.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
07-08-2025
- Business Wire
PHINIA Reports Advancements in Strategy, Innovation, and Culture in Second Annual Sustainability Report
AUBURN HILLS, Mich.--(BUSINESS WIRE)-- PHINIA Inc. (NYSE:PHIN), a leader in premium fuel systems, electrical systems, and aftermarket solutions, today released its 2024 Sustainability Report, reflecting company-wide progress across environmental, social, and governance priorities in 2024. Now in its second year, the report details PHINIA's continued investment and development in sustainable operations and innovation, circular economy practices, inclusivity and engagement, employee well-being and development, and responsible supply chain operations, among other key strategies and progress. 'We believe sustainability is not only core to responsible business — it's an important contributor to our long-term success and business strategy. Our sustainability initiatives create lasting value for our stakeholders and fuel innovation driven by our people, our purpose, and our values across engineering, operations, and culture,' said Brady Ericson, President and CEO of PHINIA. 'With this second annual report, we've moved from building a foundation to driving measurable impact. We're continuing to shape a more sustainable future for our industry and communities through data-driven decisions, global collaboration, and targeted investments.' The 2024 Sustainability Report details PHINIA's year-over-year progress and other developments across key environmental, social, and governance initiatives. Highlights from PHINIA's 2024 Sustainability Report include: Investments in More Sustainable Technologies: 89% of PHINIA's 2024 research and development (R&D) investments were dedicated to fuel efficiency and alternative fuel technologies — including for use with zero-carbon fuels and lower-carbon fuels. Hydrogen Innovation in Action: Showcased H 2 ICE developments through partnerships with Alpine Racing for its Alpenglow hydrogen-powered prototype and GCK Group and Solution F with the groundbreaking hydrogen-powered Jeep Cherokee retrofit. Operational Emissions Reductions: Reduced Scope 1 and 2 greenhouse gas (GHG) emissions by 11.7% year-over-year. Established a near-term emissions reduction goal of 50% by 2030 from a 2020 baseline year for absolute Scope 1 and 2 GHG emissions. Smart Energy Management: Reduced energy consumption by 4.5% year-over-year. Implemented a global energy monitoring system across priority manufacturing sites, which represent approximately 85% of PHINIA's total energy consumption — enabling real-time energy efficiency insights and robust trend analysis. Remanufacturing and Circular Economy Innovation: Reused 52% of the core mass of remanufactured material to return functional products back into service at its largest remanufacturing facility in 2024. Over 12 million pounds of material processed for remanufacturing at this facility since 2011. Advanced training initiatives for Design for Environment, PHINIA's process used to quantify and reduce life cycle emissions of new products. Employee Skills-Building and Well-Being: Recorded approximately 145,000 employee training hours, offered mental health first aid training opportunities, launched the global PHINIA Active wellness program, and provided other learning, development, and well-being resources and opportunities. Engaged and Inclusive Culture: Reported global employee engagement survey results, highlighting robust support of PHINIA's culture and trust in our leadership. Introduced global Inclusion strategy, expanded PHINIA Women in Science and Engineering (WISE+) program to 24 chapters across all PHINIA locations, and offered numerous other voluntary engagement opportunities available to all employees. Supply Chain Responsibility and Ethical Business: Recognized 10 suppliers for excellence, including alignment with PHINIA's sustainability expectations, through the PHINIA Partnership Program (3P). 81% of in-scope suppliers (by spend) completed sustainability self-assessments. Expanded ethics and compliance trainings initiatives and resources. PHINIA will continue building on its momentum in 2025, which for environmental-focused initiatives will include the development of a Scope 3 GHG emissions baseline and strategy, broader adoption of renewable energy across global facilities, expansion of life cycle management tools and training, and continued investments in fuel efficiency, alternative fuel systems, and technical training. 'We are proud of our progress — and even more energized by what lies ahead,' said Ericson. 'From more sustainable technologies and establishing emissions reduction goals to engaging our talent and ethical business practices, sustainability continues to guide how we innovate, operate, and grow.' For more information and to view the full 2024 Sustainability Report, please visit To connect with our global sustainability team, please contact sustainability@ About PHINIA PHINIA is an independent, market-leading, premium solutions and components provider, with over 100 years of manufacturing expertise and industry relationships and a strong brand portfolio that includes DELPHI ®, DELCO REMY ® and HARTRIDGE™. With over 12,500 employees across 43 locations in 20 countries, PHINIA is headquartered in Auburn Hills, Michigan, USA. Across commercial vehicles and industrial applications (medium-duty and heavy-duty trucks, buses and other off-highway construction, marine, agricultural and aerospace and defense), light commercial vehicles (vans and trucks) and light passenger vehicles (passenger cars, mini-vans, cross-overs and sport-utility vehicles), we develop fuel systems, electrical systems, and aftermarket solutions designed to keep combustion engines operating at peak performance, while at the same time investing in advanced technologies to unlock the potential of alternative fuels. By providing what the market needs today to become more efficient and sustainable, while also developing innovative products and solutions to contribute to lower carbon mobility, we are the partner of choice for a diverse array of customers – powering our shared journey toward a cleaner tomorrow. © 2025 PHINIA Inc. All Rights Reserved. (DELCO REMY is a registered trademark of General Motors LLC, licensed to PHINIA Technologies Inc.) Forward-Looking Statements: This press release contains forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical facts that provide current expectations or forecasts of future events based on certain assumptions and are not guarantees of future performance. Forward-looking statements use words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'designed,' 'effect,' 'estimate,' 'evaluate,' 'expect,' 'forecast,' 'goal,' 'initiative,' 'intend,' 'likely,' 'may,' 'outlook,' 'plan,' 'potential,' 'predict,' 'project,' 'pursue,' 'seek,' 'should,' 'target,' 'when,' 'will,' 'would,' and other words of similar meaning. Forward-looking statements are subject to risks, uncertainties, and factors relating to our business and operations, all of which are difficult to predict, and which could cause our actual results to differ materially from the expectations expressed in or implied by such forward-looking statements. Risks, uncertainties, and factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: adverse changes in general business and economic conditions, including recessions, adverse market conditions or downturns impacting the vehicle and industrial equipment industries; our ability to deliver new products, services and technologies in response to changing consumer preferences, increased regulation of greenhouse gas emissions, and acceleration of the market for electric vehicles; competitive industry conditions; failure to identify, consummate, effectively integrate or realize the expected benefits from acquisitions or partnerships; pricing pressures from original equipment manufacturers (OEMs); inflation rates and volatility in the costs of commodities used in the production of our products; changes in U.S. and foreign administrative policy, including tariffs, changes to existing trade agreements and import or export licensing requirements, and any resulting changes in international trade relations; our ability to protect our intellectual property; failure of or disruption in our information technology infrastructure, including a disruption related to cybersecurity; our ability to identify, attract, retain and develop a qualified global workforce; difficulties launching new vehicle programs; failure to achieve the anticipated savings and benefits from restructuring and product portfolio optimization actions; extraordinary events, including natural disasters or extreme weather events, fires or similar catastrophic events, political disruptions, terrorist attacks, pandemics or other public health crises, and acts of war; risks related to our international operations; the impact of economic, political, social and market conditions on our business in China; our reliance on a limited number of OEM customers; supply chain disruptions, including due to U.S. and foreign government action; work stoppages, production shutdowns and similar events or conditions; governmental investigations and related proceedings regarding vehicle emissions standards, including the ongoing investigation into diesel defeat devices; current and future environmental, health and safety, human rights and other laws and regulations; the impacts of climate change, regulations related to climate change and various stakeholders' emphasis on climate change and other related matters; compliance with and changes in other laws and regulations; liabilities related to product warranties, litigation and other claims; tax audits and changes in tax laws or tax rates taken by taxing authorities; impairment charges on goodwill and indefinite-lived intangible assets; the impact of changes in interest rates and asset returns on our pension funding obligations; the impact of restrictive covenants and other requirements on our financial and operating flexibility pursuant to the agreements governing our indebtedness; risks relating to the spin-off from our former parent, including our ability to achieve some or all of the benefits that we expect to achieve from the spin-off, a determination that the spin-off does not qualify as tax-free for U.S. federal income tax purposes, and our or our former parent's failure to perform under, or additional disputes that may arise between the parties 4 relating to, various transaction agreements executed in connection with the spin-off; and other risks and uncertainties described in our reports filed from time to time with the Securities and Exchange Commission. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Yahoo
04-08-2025
- Yahoo
Picture this: Is it worth $5000?
Reading through the photography news of the month, I came across several reviews and recommendations for a new camera, the Sony RX1 III. As my readers know, I am all about cameras and lenses, so sure, I thought, I'd love to learn about this new Sony. The RX1 III is a fixed-lens, 60 megapixel, 36x24mm-sized sensor, 'rangefinder style', 'premium compact' camera. It shoots at five frames per second, and sports a 35mm f/2.0 Zeiss Sonnar lens. I assume the image quality you can get from a camera like this is excellent, but I assume that about most of the cameras I see and use, because it's true. But the lingering question about this particular camera is the price: $5000. Wait, Richard, don't you mean... $500? No, read it again. Look it up. $5000. So in my mind, I circle back to image quality, and wonder if the amazing images I make all the time with cranky, well-warn, cameras from a decade ago would be made better, and in what way, by a $5000 camera. I try not to be stubborn, but I was originally from Missouri, so show me. If you buy this camera and make an amazing image with it, bring it to me in some valuable form, like in a book or a very large print, and let me be amazed. Solve the daily Crossword
Associated Press
29-07-2025
- Associated Press
betterview Reaches 20,000 Eyes Treated in Four Years
WINTERTHUR, Switzerland--(BUSINESS WIRE)--Jul 29, 2025-- betterview, a Swiss provider of refractive eye surgery, has announced that it has reached the milestone of 20,000 eyes treated since its founding in 2021. Since its launch, the company has built a network of ten clinics and its own surgical center, covering all language regions of Switzerland. This continued expansion has positioned betterview as one of the country's leading providers of laser vision correction. betterview offers a range of refractive surgery procedures, including Femto-LASIK, Trans-PRK, and the modern SMILE Pro method. Treatments are performed using advanced laser systems from manufacturers such as Alcon and Zeiss. In early 2025, the company introduced the SMILE Pro procedure, a minimally invasive laser eye surgery technique. Utilizing the ZEISS VisuMax 800 laser system, the procedure can reduce treatment time to under 10 seconds per eye. The company's growth is driven by a combination of cutting-edge technology, transparent pricing, and patient care. Financing options are available starting at CHF 90 per month. betterview's strategy emphasizes both geographic accessibility and continuous innovation. The 20,000 eyes treated include procedures across all clinic locations and methods, reflecting steady growth since the company's inception. betterview is also the first company in Swiss ophthalmology to establish an independent ombuds office in partnership with the national consumer forum. This offers patients a neutral point of contact for inquiries or complaints and underscores the company's commitment to patient rights and transparency. Since 2021, betterview's ongoing expansion has made it one of the leading laser eye correction providers in Switzerland, with a focus on innovation and nationwide availability. About betterview Founded in 2021 in Winterthur, betterview specializes in refractive eye surgery. The company operates clinics in Zurich, Bern, Basel, Aarau, Lucerne, St. Gallen, Chur, Lugano, and Geneva. Its services include various laser procedures to correct nearsightedness, farsightedness, and astigmatism. betterview uses technology from leading manufacturers such as Alcon and Zeiss, offering treatment methods including Femto-LASIK, Trans-PRK, and SMILE Pro. The company follows a fixed-price model with flexible financing options. All locations are in urban areas and exclusively focus on laser vision correction. Since its founding, betterview has consistently invested in new technologies and expanded its network of locations. The company prioritizes high standards of care and transparent pricing. For more information, View source version on CONTACT: Media Contact: betterview AG Zürcherstrasse 464 8400 Winterthur Switzerland Phone:+41 52 260 20 30 Email:[email protected] Web: KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH OPTICAL SURGERY SOURCE: betterview Copyright Business Wire 2025. PUB: 07/29/2025 03:48 AM/DISC: 07/29/2025 03:48 AM
